30. Sherlock S, Doley J. Hepatitis C virus. Diseases of the liver and biliary system. Chapter 16, 10th edition, BaIckwell-Science, Oxford, DK. 1997:289-296
31. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2003; 358;958-965
32. Esteban JT, Talawara JC, Geneco J et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991;115:443-449
33. Alter MJ. Epidemiology ofhepatitis C in the West. Semin Liver Dis 1995;15:5-14
34. Seef CB. Hepatitis C from a needlestick injury. Ann Intern Med 1991;115:411
35. Kiyosawa K, Sadeyama T, Tonoha E. et al. Hepatitis C virus infection in healt care workers. Viral Hepatitis and Liver Disease. Tokyo: Sprigger, Verlog. 1994;479-482
36. Polish LB, Tong MJ, Co RL, et al. Risk factors for hepatitis C virus infection among health care personnel in a community hospital. Am J Infect Control 1993;21:196-200
37. Kiyosawa K, Di Biceglie AM. Hepatitis C Lancet 1998;251:351-355 38. Iyosawa K, Sadeyama T, Tonoha E et al. Hepatitis C in hospital
employees with needlestick injuries. Ann Intem Med. 1999;115:367-369 39. Alter MJ. Hepatitis C virus in the United States. J Hepatol 1999;31 :88-91 40. Panlilio AL, Shapiro EN, Schabl CA, et al. Serosurvey of immundeficiency
virus, hepatitis B virus, and hepatitis C virus infection among hospital based surgeons. J Am Coll Surg 1995;180:16-24 41. Akkız H, HCV enfeksiyonu. Epidemiyoloji ve korunma. Viral Hepatit 2001, Viral Hepatitle Savaşım Derneği, Ed. K. KıIıçturgay, Nobel Tıp Kitabevi, İstanbul 193-208
57



65. SAYFAYA BENZER SAYFALAR

tabs_sener_yagiz_191898 - Sayfa
...


65. SAYFA ICERIGI

30. Sherlock S, Doley J. Hepatitis C virus. Diseases of the liver and biliary system. Chapter 16, 10th edition, BaIckwell-Science, Oxford, DK. 1997:289-296
31. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2003; 358;958-965
32. Esteban JT, Talawara JC, Geneco J et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991;115:443-449
33. Alter MJ. Epidemiology ofhepatitis C in the West. Semin Liver Dis 1995;15:5-14
34. Seef CB. Hepatitis C from a needlestick injury. Ann Intern Med 1991;115:411
35. Kiyosawa K, Sadeyama T, Tonoha E. et al. Hepatitis C virus infection in healt care workers. Viral Hepatitis and Liver Disease. Tokyo: Sprigger, Verlog. 1994;479-482
36. Polish LB, Tong MJ, Co RL, et al. Risk factors for hepatitis C virus infection among health care personnel in a community hospital. Am J Infect Control 1993;21:196-200
37. Kiyosawa K, Di Biceglie AM. Hepatitis C Lancet 1998;251:351-355 38. Iyosawa K, Sadeyama T, Tonoha E et al. Hepatitis C in hospital
employees with needlestick injuries. Ann Intem Med. 1999;115:367-369 39. Alter MJ. Hepatitis C virus in the United States. J Hepatol 1999;31 :88-91 40. Panlilio AL, Shapiro EN, Schabl CA, et al. Serosurvey of immundeficiency
virus, hepatitis B virus, and hepatitis C virus infection among hospital based surgeons. J Am Coll Surg 1995;180:16-24 41. Akkız H, HCV enfeksiyonu. Epidemiyoloji ve korunma. Viral Hepatit 2001, Viral Hepatitle Savaşım Derneği, Ed. K. KıIıçturgay, Nobel Tıp Kitabevi, İstanbul 193-208
57

İlgili Kaynaklar







single.php